Clinica De Oftalmologia De Cordoba S.L.

Cordoba 20 trials 5 recruiting

20 Registered trials

5 Currently recruiting

Organisation

Clinica De Oftalmologia De Cordoba S.L.

Location

Cordoba, Spain

Identifier

ORG-100044251

Address

Avenida De La Arruzafa 9, 14012, Spain

Departments

#2106: Oftalmología
201: Oftalmología
2106:Instituto de Oftalmología La Arruzafa
2106:Oftalmología
Instituto de Oftalmología La Arruzafa
NA
Oftalmología
Ophtalmology
Ophthalmology
Ophthalmology service
Servicio de Oftalmologia

Clinical trials at this site (20)

Search interface

An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Pending

2025-523443-35-00 Persistent Corneal Epithelial Defect (PCED) 5
Study to Assess K1-70 in Participants with Active Thyroid Eye Disease Recruiting

2024-519292-26-00 Graves’ disease and active thyroid eye disease 4 2026-05-28
A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting

2024-514801-69-00 Thyroid Eye Disease 4 2025-04-02
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) Recruiting

2024-514972-42-00 Thyroid eye disease 5 2025-02-25
Study to Assess the Ability of ONL1204 to Slow the Progression of Atrophic Age-related Macular Degeneration Recruiting

2024-513174-22-00 Atrophic Age-related Macular Degeneration (AMD) 4 2026-04-14
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 … Recruiting

2022-500747-21-00 Geographic Atrophy 4 2025-02-27
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) Ended

2024-514973-23-00 Thyroid eye disease 5 2025-02-25
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended

2023-503666-23-00 Neovascular age-related macular degeneration 5 2024-06-07
A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended

2023-507131-38-00 Neovascular Age-Related Macular Degeneration (nAMD) 5 2022-05-16
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509198-22-00 Thyroid Eye Disease (TED) 5 2024-10-21
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended

2023-507350-33-00 Thyroid eye disease 5 2024-06-25
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended

2023-507217-10-00 Thyroid eye disease 5 2024-04-12
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended

2023-506707-25-00 Choroidal neovascularization secondary to pathologic my 5 2024-04-09
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease Ended

2023-508161-32-00 Thyroid Eye Disease 4 2024-03-28
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
N/A Ended

2024-515090-96-00 Thyroid Eye Disease 11 2022-05-10
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Ended

2023-508571-37-00 Geographic atrophy (GA) secondary to Age-related Macula 4 2022-04-29
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Neovascular age-related macular degeneration (wet AMD) 5 2021-09-23
OXU-001 compared to Intravitreal Ozurdex for the Treatment of Diabetic Macular Edema Ended

2023-503496-17-00 Diabetic Macular Edema (DME) 4